# CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

> **NCT05689021** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 8 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Abiraterone Acetate/Niraparib
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05689021
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05689021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05689021, "CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT05689021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*